Castro Catarina, Marques João Heitor, Marta Ana, Baptista Pedro Manuel, José Diana, Sousa Paulo, Menéres Pedro, Barbosa Irene
Ophthalmology, Centro Hospitalar Universitário de Santo António, Porto, PRT.
Cureus. 2023 Jul 5;15(7):e41386. doi: 10.7759/cureus.41386. eCollection 2023 Jul.
To compare different light-based devices, namely, intense pulsed light (IPL) and IPL with low-level light therapy (LLLT), in the treatment of meibomian gland dysfunction (MGD).
This was a prospective, observational study that included patients with MGD. Group 1 included 58 eyes treated with IPL (eye-light®, Espansione Marketing S.p.A., Bologna, Italy), followed by LLLT (my-mask®, Espansione Marketing S.p.A., Bologna, Italy); Group 2 included 60 eyes treated with IPL (E>Eye®, E-Swin, Houdan, France); and Group 3 included 58 eyes treated with IPL (Thermaeye Plus®, OptiMed, Sydney, Australia). The presence of symptoms (Ocular Surface Disease Index (OSDI)) and ocular surface changes were evaluated at baseline, three weeks, and six months after treatment.
At week three, there was an improvement in the OSDI in all groups (p<0.001), without differences among them (p=0.339). The lipid layer thickness (LLT) increased in Groups 1 and 2 (p<0.001), with a similar variation (p=0.144). Patients with superior OSDI and lower LLT at baseline had the greatest improvement in the respective parameters (p<0.001). The basal tear flow increased in Group 1 (p=0.012). Corneal staining (CS) significantly decreased in Groups 2 (p<0.001) and 3 (p<0.001). At six months, compared to three weeks, there was further improvement in the OSDI (p<0.001) and the LLT (p=0.007), in Group 1, and an increase in the presence of CS in Group 3 (p=0.011).
IPL treatment led to a sustained decrease in patients' symptoms, even after six months. Different IPL devices seem to have different beneficial effects. Adding LLLT to IPL appears to have an additional long-term beneficial effect as well as positive effects on the lacrimal gland.
比较不同的光基设备，即强脉冲光（IPL）和联合低强度光疗法（LLLT）的IPL，用于治疗睑板腺功能障碍（MGD）。
这是一项前瞻性观察研究，纳入了MGD患者。第1组包括58只接受IPL治疗（eye-light®，Espansione Marketing S.p.A.，博洛尼亚，意大利），随后接受LLLT治疗（my-mask®，Espansione Marketing S.p.A.，博洛尼亚，意大利）的眼睛；第2组包括60只接受IPL治疗（E>Eye®，E-Swin，乌丹，法国）的眼睛；第3组包括58只接受IPL治疗（Thermaeye Plus®，OptiMed，悉尼，澳大利亚）的眼睛。在治疗前、治疗后三周和六个月评估症状（眼表疾病指数（OSDI））的存在情况和眼表变化。
在第三周时，所有组的OSDI均有所改善（p<0.001），但组间无差异（p=0.339）。第1组和第2组的脂质层厚度（LLT）增加（p<0.001），变化相似（p=0.144）。基线时OSDI较高且LLT较低的患者在各自参数上改善最大（p<0.001）。第1组的基础泪液流量增加（p=0.012）。第2组（p<0.001）和第3组（p<0.001）的角膜染色（CS）显著减少。在六个月时，与三周相比，第1组的OSDI（p<0.001）和LLT（p=0.007）进一步改善，第3组的CS出现率增加（p=0.011）。
IPL治疗即使在六个月后也能使患者症状持续减轻。不同的IPL设备似乎有不同的有益效果。在IPL基础上加用LLLT似乎有额外的长期有益效果，以及对泪腺的积极作用。
